Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2012

View Archived Issues

Researchers at Leo Pharma patent novel ingenol compounds

Candidate Syntaxin drug for acromegaly has new mode of action

New NK3 receptor antagonists presented by Roche

New antifungals prepared at Janssen Pharmaceutica

Eutropics Pharmaceuticals discloses novel Mcl-1/Bcl-XL inhibitors

New IGF-I receptor inhibitors reported by Boehringer Ingelheim

Janssen Pharmaceutica divulges new BACE1 inhibitors

Belgian-Dutch collaboration yields candidate biomarker for use in kidney transplant recipients

Novel OGA inhibitors designed

BioCryst reports on two phase II trials of BCX-4208

Data presented on sustained-release plug for glaucoma

Recruitment begins in phase II NKTR-181 trial

First preclinical candidate drug selected in osteoarthritis alliance

Merck & Co. provides update on anti-HIV drug development

Dynavax submits MAA for Heplisav hepatitis B vaccine

Sarepta drug shows clinical benefit in Duchenne muscular dystrophy

Ongoing conference features new data on anti-HIV/HSV combination gel

Pfizer reports topline results from first of four phase III bapineuzumab studies

First patient treated in study of subcutaneous Debio-8206

Biofrontera holds meeting with FDA regarding planned application for Ameluz

FDA grants priority review to enzalutamide NDA

FDA issues safety communication regarding Ampyra

Anticancer drug shows promise to treat Alzheimer's disease

Psyadon halts ecopipam study based on promising interim results

SRI receives NIAID grant for development of bioadhesive gel

European Commission approves combination tablet for type 2 diabetes

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...